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Abstract
Background: To compare final height to mid-parental target height among adults with childhood-onset
systemic lupus erythematosus (cSLE) versus adult-onset SLE (aSLE), and to evaluate the impact of age at SLE
onset on final height.
Methods: Data derived from the Lupus Outcomes Study, a longitudinal cohort of adults with SLE, was used for this
cross-sectional analysis (N = 728). Participants aged 18–63 years with complete height data were included (N = 566)
and were classified as cSLE if age at diagnosis was < 18 years (N = 72). The Tanner formula was used to calculate mid-
parental target height. Multivariate linear regression was used to determine mean difference between final height and
target height. Multivariate logistic regression was used to compare odds of substantially reduced final height, defined
as > 2 SD below target height. Separate analyses were conducted for females and males to account for differences in
timing of the pubertal growth spurt for each sex.
Results: Participants with cSLE were, on average, 2.4 cm shorter than their target height (95% CI -4, − 0.7). The adjusted
odds ratio (OR) for substantially reduced final height was 3.9 (95% CI + 2.0, + 7.2, p < 0.001) as compared to participants
with aSLE. Females diagnosed between 11 and 13 years were at greatest risk for substantially reduced final height, with
adjusted OR of 11.2 (95% CI + 3.4, + 36.3) as compared to participants with aSLE (p < 0.001).
Conclusions: cSLE is associated with shorter-than-expected final height. Onset of SLE in the pubertal period, near the
time of maximum linear growth, may have a particularly significant impact on final height.
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Background
Childhood-onset systemic lupus erythematosus (cSLE) is
a multi-system autoimmune disease characterized by
autoantibody production. It is estimated to account for
10% to 20% of all cases of systemic lupus erythematosus
(SLE), with an average age at onset of 12 years [1].
cSLE is often more severe than adult-onset SLE (aSLE),
with higher levels of disease activity, greater likelihood of
renal and neurological involvement, lower complement
levels and a more frequent need for immunosuppressive
therapy [2–5]. Survival in SLE has improved dramatically,
from five-year survival rates of 42–72% in the 1960’s to
95% today [6–8]. As a result, SLE in adults and children
has shifted from being a predominantly fatal disease to a
chronic condition [9, 10]. As life expectancy of children
with SLE has increased, assessing outcomes of the disease,
including the effects of therapy, has become increasingly
important.
Impaired linear growth is commonly encountered in
children with chronic inflammatory conditions, inclu-
ding SLE. These children may experience delayed onset
of puberty and attenuated pubertal growth spurts, espe-
cially when the disease presents in late childhood or
early adolescence [11, 12]. Poor growth may lead to
short stature, and ultimately shorter-than-expected adult
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height, which may impact quality of life [11]. Multiple
factors may contribute to the underlying pathophysi-
ology of growth failure in chronic illness, including
suboptimal nutrition, prolonged use of glucocorticoids,
comorbidities and the chronic inflammatory process it-
self [11, 13]. Growth failure may result from suppression
of the Growth Hormone (GH)-IGF-1 axis or at the level
of the growth plate [11].
Significant differences between target and final adult
height has been shown in systemic-onset juvenile
idiopathic arthritis (sJIA), although these reports do not
reflect the more recent outcomes of patients treated
with biologics, which may reduce steroid use and subse-
quent growth impairment [11, 14]. Studies of adults with
childhood-onset inflammatory bowel diseases (IBD) also
reveal a difference between target and actual height [11],
especially in males [15]. In a cohort of 123 patients with
pediatric onset Crohn’s disease, mean adult height was 2.
4 cm less than target height, and 19% of patients were
more than 8 cm shorter than their target height [16].
Growth failure was added to the Modified SLICC/ACR
SLE Damage Index (M-SDI) by Bandeira et al. [17] and
Gutierrez-Suarez et al. [18] as a damage measure for
pediatric SLE. Although Bandeira et al. documented
growth failure in 15.8% at 3 years of follow up of cSLE,
the percentage of participants with growth failure was
smaller (7.7%) at 5 years of follow up, demonstrating the
potential for catch-up growth in children. As a result,
Hiraki et al. proposed final height as a preferred measure
of damage in pediatric SDI [12], recognizing that only
reduced final height represents an irreversible outcome,
since children with cSLE and growth failure may experi-
ence significant catch-up growth once the disease is
better controlled and steroid dose is tapered.
The purpose of this study was to assess final adult
height in an adult cohort of patients with both cSLE and
aSLE, comparing final height to target height and evalu-
ating the impact of age of SLE onset on final height. To
our knowledge, this work represents the first study of
final adult height in cSLE.
Patients and methods
Data sources
Data was derived from the 2007 cycle of Lupus Outcome
Study (LOS) (Fig. 1). The LOS is a longitudinal, U.S.-
based cohort of over 1200 adults with SLE, 10% of
whom had disease onset in childhood (defined as age at
diagnosis < 18 years). Details regarding LOS eligibility
and enrollment are described elsewhere [19]. Briefly,
participants were recruited from community (70%) and
clinical (30%) sources, with data collected annually via
telephone by trained interviewers. All participants had a
confirmed diagnosis of SLE according to chart review
supervised by a rheumatologist, using the American
College of Rheumatology (ACR) classification criteria for
SLE [20]. The survey included validated items pertaining
to demographic and socioeconomic characteristics, SLE
manifestations, medications, general health, mental
health, cognition, employment, and health care
utilization. All study data were obtained by participant
self-report.
a b
a
b
Fig. 1 Study Population of Adults with SLE from the Lupus Outcome Study included in the Analysis
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Measures
The primary outcome measures for this analysis were 1)
difference between patient-reported final adult height and
mid-parental target height, and 2) substantially reduced
final height. Target height was calculated from patient-
reported biologic-parent heights using the Tanner
formula, a validated measure used to estimate genetic
height potential: mean parental height plus 6.5 cm for
males, and mean parental height minus 6.5 cm for females
[21]. Substantially reduced final height was defined as final
adult height more than 2 standard deviations (SD) below
the mid-parental target height, consistent with the clinical
definition of short stature [22]. The SD for the target
height in the general population is approximately 2.5 cm
[23]; therefore, we identified patients with final adult
height more than 5 cm below the target height as having
substantially reduced final height.
The primary predictor variable was cSLE, defined as
age < 18 years at diagnosis. To further explore the
impact of age at SLE onset on final adult height, we sub-
divided the cSLE cohort into groups based on age at
disease onset (< 11, 11–13, 14–15, 16–17 years). Age
groups were defined based on timing of pubertal growth
spurts in healthy girls and boys. On average, the pubertal
growth spurt occurs between the ages of 11 and 13 years
in females and 14 to 15 years in males. Demographic
predictors included sex and race/ethnicity. Race/ethni-
city was categorized as White, Hispanic, African
American, Asian and other. SLE-associated predictors
included year of diagnosis, disease duration, steroid use
ever, cyclophosphamide use ever, and history of end-
stage renal disease (defined as history of dialysis or
kidney transplant). Year of diagnosis was included in the
final model as a predictor to account for the changes in
the standard of care for SLE over time. Cyclophospha-
mide use and end-stage renal disease (ESRD) were
included as proxies for disease severity.
Study sample
Data from the 2007 cycle of the LOS were used for this
cross-sectional analysis (N = 728). All participants age
18–63 years with complete height data were included
(N = 566). Since the oldest participant with cSLE was
63 years old at time of interview, aSLE patients age >
63 years were excluded (N = 116) in order to maximize
overlap between groups, as well as to avoid the potential
confounding effect of linear height loss among elderly
participants.
Statistical analysis
Baseline characteristics of the cSLE and aSLE groups
were summarized and compared using bivariate statistics
(Student’s t-test, rank sum and chi-square test), as
appropriate. Multivariate linear regression was used to
determine adjusted and unadjusted mean differences be-
tween final adult height and target height. Multivariate
logistic regression was used to compare unadjusted and
adjusted odds of substantially reduced final height be-
tween participants with cSLE and aSLE. The final
models included cSLE vs. aSLE status, sex, race/ethnicity
and predictors of substantially reduced final height with
p < 0.2 in univariate analysis among participants with
cSLE (year of diagnosis, cyclophosphamide use and
ESRD).
Among participants with cSLE, one-way ANOVA
testing was used to determine whether the difference be-
tween final and target height varied according to timing
of cSLE onset (age < 11, 11–13, 14–15, 16–17 years).
Separate ANOVA analyses were conducted for females
and males to account for differences in the average
timing of the pubertal growth spurt, and post-hoc Tukey
testing was conducted to account for multiple
comparisons.
Bivariate and multivariate logistic regression analyses
were conducted to determine whether timing of SLE on-
set is associated with significantly shorter-than-expected
final height among female participants with cSLE.
Analyses were not conducted for males alone due to the
small number of male participants.
Finally, to further explore the impact of disease se-
verity on final height among individuals with cSLE,
we examined the association between substantially re-
duced final height and history of cyclophosphamide
treatment in the cSLE cohort, using univariate and
multivariate logistic regression. Covariates included
sex, race/ethnicity, timing of cSLE onset (age < 11,
11–13, 14–15, 16–17 years), year of diagnosis and
history of ESRD. Statistical analyses were performed
using STATA 13.0 (StataCorp, College Station, TX.)
Results
Demographics
The study population consisted of 566 participants with
SLE, including 72 (13%) with cSLE. The baseline charac-
teristics of the cSLE and aSLE subgroups are described
in Table 1. As compared to participants with aSLE, those
with cSLE were younger at the time of the interview
(mean age 33 ± 9 versus 49 ± 9 years; p < 0.001), more
likely to be male (12% versus 6%; p = 0.01) and less likely
to be white (51% versus 70%; p < 0.001). Mean age at
diagnosis was 14 ± 3 versus 33 ± 10 years (p < 0.001),
with ranges of age of diagnosis being 2–17 and 18–58
respectively. Respondents with cSLE were more likely to
have ever required dialysis (18% versus 7%; p = 0.001)
and to have undergone kidney transplantation (14% ver-
sus 5%; p = 0.003). All cSLE participants and nearly all
aSLE participants reported a history of steroid use (100%
versus 94%; p = 0.02). There was no difference between
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groups in the likelihood of having received cyclophos-
phamide (14% versus 13%; p = 0.9).
Impact of age at SLE onset on final height
In bivariate analysis, participants with cSLE were, on
average, 2.4 cm shorter than their target height (95% CI
-4, − 0.7). This differed significantly from aSLE partici-
pants (p < 0.001), who were a mean of 0.6 cm taller than
expected (95% CI 0.03, 1.1). When dividing the groups
by sex, females were on average 2.5 cm shorter than
their target height (95% CI -4.3, − 0.6), as compared to
aSLE (p < 0.001). Males were 2 cm shorter than their tar-
get height, but the difference was not significant (95% CI
-7.5, 3.6, p = 0.2) (Fig. 2). In a multivariate linear regres-
sion model controlling for sex, race/ethnicity, year of
SLE diagnosis, cyclophosphamide use and ESRD, indi-
viduals with cSLE were on average 2.8 cm shorter than
their target height (95% CI -4.2, − 1.3), and this also
differed significantly as compared to aSLE individuals
(p < 0.001), who were on average 0.6 cm taller than ex-
pected (95% CI 0.07, 1.2).
Among cSLE participants, mean difference between
actual and target height differed significantly according
to age at disease onset (p < 0.001, Fig. 3). Females with
cSLE diagnosed between 11 and 13 years old were
shorter than expected by 6.8 cm (95% CI -11.7, − 1.8),
which differed significantly from females with aSLE
(p < 0.001), who were on average 0.5 cm taller than ex-
pected (95% CI -0.0, + 1.1). In a multivariate linear re-
gression model controlling for race/ethnicity, year of
SLE diagnosis, cyclophosphamide use and ESRD, females
with cSLE diagnosed between 11 and 13 years old were
on average 8 cm shorter than their target height (95% CI
-11, − 5), p < 0.001. Females diagnosed at 14 or 15 years
old were shorter than expected by 0.5 cm, which
approached statistical significance when compared to fe-
males diagnosed at 11–13 years (95% CI -3, + 2, p = 0.06).
Males diagnosed with SLE at the youngest ages (< 11, 11–
13, 14–15) were on average shorter than expected, while
males diagnosed at age 16–17 or in adulthood were on
average taller than expected. However, these differences
did not reach statistical significance.
Finally, we compared the odds of substantially reduced
final height, or actual height more than 2 SD (> 5 cm)
below target height. A higher proportion of cSLE partici-
pants had substantially reduced final height when com-
pared to the adult-onset group (31% vs 14%, p < 0.001).
In logistic regression analyses, participants with cSLE
were more likely to have substantially reduced final
height, with an unadjusted OR of 2.8 (95% CI + 1.6, + 4.
9, p < 0.001). After adjustment for sex, ethnicity/race,
year of SLE diagnosis, cyclophosphamide use and ESRD,
the odds of short stature in cSLE participants rose to 3.9
(95% CI + 2.0, + 7.2, p < 0.001). Females diagnosed be-
tween the ages of 11 and 13 years were at greatest risk
for substantially reduced final height, with unadjusted
odds ratio of 6.3 (95% CI + 2.3, + 17.3, p < 0.001) and ad-
justed odds ratio of 11.2 (95% CI + 3.4, + 36.3; p < 0.001)
as compared to participants with aSLE (Fig. 4).
Impact of cyclophosphamide on substantially reduced
final height
Individuals in the cSLE cohort who received cyclophos-
phamide were clinically significant shorter in univariate
analysis (27% vs 8%, p = 0.03). In multivariate logistic
regression analysis accounting for sex, race/ethnicity,
timing of cSLE onset (age < 11, 11–13, 14–15, 16–
17 years), year of diagnosis and history of ESRD, cSLE
participants with history of cyclophosphamide use were
again much more likely to demonstrate substantially
reduced final height, with an adjusted OR of 9.0
(95% CI + 1.5, + 53, p = 0.01).
Discussion
In this cohort of adults with SLE, we found that individ-
uals with cSLE were significantly less likely to reach their
target height as compared to those with adult-onset SLE.
Our results further demonstrate that onset of SLE in the
pubertal period, a time of rapid linear growth, may have
a particularly significant impact on final adult height.
Table 1 Baseline characteristics of childhood and adult onset
SLE patients enrolled in Lupus Outcome Study
Variable cSLEa
(N = 72)
aSLEb
(N = 494)
p-value
Sociodemographics N (%) or Mean ± SD
Age at diagnosis, years 14 ± 3 33 ± 10 < 0.001
Age at interview, years 33 ± 9 49 ± 9 < 0.001
Sex, female 63 (88%) 465 (94%) 0.01
Race/Ethnicity (%) < 0.001
White 37 (51%) 347 (70%)
Hispanic 11 (15%) 39 (8%)
African American 5 (7%) 35 (7%)
Asian 11 (15%) 50 (10%)
Other 8 (11%) 23 (5%)
SLE Characteristics
Dialysis ever (A) 13 (18%) 34 (7%) 0.001
Renal transplant ever (B) 10 (14%) 24 (5%) 0.003
End-stage ever (A and/or B) 15 (21%) 37 (7%) < 0.001
Treated w Steroids ever 72 (100%) 465 (94%) 0.02
Treated w Cyclophosphamide
ever
10 (14%) 66 (13%) 0.9
acSLE = Childhood-onset Systemic Lupus Erythematosus
(diagnosis age < 18 years)
baSLE = Adult-onset Systemic Lupus Erythematosus (diagnosis age 18+ years)
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Due to the rarity of cSLE and the lack of longitudinal
cohort studies, information regarding growth and final
height in cSLE has been limited. In a cross-sectional
study of 1015 cSLE patients with a mean age of 15.
9 years, growth failure, defined as height more than 2
standard deviations (SD) below the mean for age, was
reported in 15.3% [18]. No information on target height
or final adult height was included. Another cross-
sectional study of 70 patients with cSLE found that
mean height of the cohort was significantly lower than
healthy matched controls; however, this cohort consisted
of patients aged 9–49 years, and therefore did not reflect
the final adult height for all patients, and did not take
into account the target height for each individual [24].
In a similar study that examined 32 cSLE patients for a
mean period of 4.3 years during the 1980s, short stature
(defined as height for age less than the 5th percentile)
was present in 38%. This study also did not include final
height for all participants [25]. In a longitudinal study,
the Paediatric Rheumatology International Trials
Organization (PRINTO) examined growth in 331 cSLE
patients with a median age of 13.9 years over 26 months,
comparing patients’ height to mid-parental height [26].
At the end of the study period, growth failure (defined
as a parental height z-score < − 1.5) was seen in 15% of
the female patients and 25% of the male patients.
Furthermore, growth failure was seen in 22.4% of
women with disease onset before the age of 12 com-
pared to 3.3% of women with disease onset after 12 years
of age. Again, final adult height was not assessed.
Timing of the pubertal growth spurt is different in
males and in females. The pubertal growth spurt in fe-
males occurs during early adolescence. The peak linear
growth velocity corresponds most closely with Tanner
stage 2 in females, which occurs in 95% of the girls by
the age of 12.1 years. For males, the growth spurt occurs
later in puberty, around Tanner stage 3 and age 14 years
[23]. The differences between females and males in our
analysis can be partially explained by this difference in
timing of the pubertal growth spurt. In our analysis, SLE
onset in females around the age of peak linear growth
(11–13 years old) was associated with significantly shorter
than expected adult height, whereas SLE diagnosed later
in puberty (age 14–15 years and 16–17 years), after the
growth spurt is completed for most females, did not sig-
nificantly affect final adult height. Males demonstrated
similar results, though these findings did not achieve stat-
istical significance, likely due to the very small number of
male participants in our study. Males who were diagnosed
around the time of peak linear growth (age 14–15 years)
were shorter than expected by a mean of 3.6 cm. Disease
onset between ages 11 to 13 years in males did affect final
height as well, but to a lesser extent than in the female
population.
Final height greater than 2 SD below the mid-
parental height (> 5 cm) has been previously
suggested by Hiraki et al. as a damage measure in
cSLE [12]. In our analyses, individuals with cSLE were
more than three times more likely to meet this crite-
rion as compared to the aSLE population. Odds of
a b
a
b
Fig. 2 Mean difference between final height and mid-parental target height among participants with childhood-onset versus adult-onset SLE, by
sex (n = 566). This graph demonstrates the mean difference between final height and mid-parental target height among males and females with
cSLE and aSLE. Females with cSLE were on average 2.5 cm shorter than their target height (95% CI -4.3, − 0.6) which differed significantly from
females with aSLE (p < 0.001). Males with cSLE were on average 2 cm shorter than target height, but did not differ significantly from males with
aSLE (95% CI -7.5, 3.6, p = 0.2)
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short stature were the greatest among females diag-
nosed between the ages of 11–13 years.
Our analyses demonstrated that childhood-onset lupus
patients with a history of cyclophosphamide exposure
may be at significantly higher risk for reduced final
height. As individuals with cSLE who receive cyclophos-
phamide typically have severe disease, they are likely to
have had higher levels of systemic inflammation and
steroid exposure, both of which can inhibit linear
growth.
Although to date recombinant GH therapy is not indi-
cated in the treatment of chronic inflammatory disease,
cSLE patients with significant short stature may be
considered for GH therapy in the future. In other
inflammatory diseases like juvenile idiopathic arthritis,
randomized controlled trials have confirmed that GH
therapy can improve final adult height and also suggest
a modest effect on short to medium term catch-up
growth [11]. The benefit versus risk from GH therapy
should be considered, with the main risks being decrease
in insulin sensitivity, skeletal complications like avascu-
lar necrosis, increased risk of malignancies and the the-
oretical risk of worsening the inflammatory disease
process itself. In the literature, there are only case re-
ports of GH therapy in cSLE. Gorska et al. reports on
GH therapy given to a 17-year-old female patient with
a
b
Fig. 3 Mean difference between final height and mid-parental target height among participants by age at SLE diagnosis. a Mean difference
between final height and mid-parental target height among females with SLE, by age at lupus diagnosis. Females diagnosed between 11 and
13 years of age were shorter than expected by 6.8 cm (95% CI -11.7, −1.8), which differed significantly from females diagnosed later in childhood
(14–15, 16–17 years) or during adulthood. b Males diagnosed with SLE at the youngest ages (< 11, 11–13, 14–15) were on average shorter than
expected, while males diagnosed at age 16–17 or in adulthood were on average taller than expected. However, these differences did not reach
statistical significance
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short stature and bone age of 11 years [27]. Following
one-year of GH therapy, the girl achieved catch-up
growth, with no significant side effects. Bae et al.
reported a case of a 19-year-old man with a history of
cSLE, treated with GH and testosterone at the age of 16
for hypogonadism and growth impairment [28]. Nine
months after GH initiation, height increased by 10 cm.
However, GH therapy was discontinued due to increased
disease activity, which improved after cessation of GH
therapy. Yap et al. described improved growth velocity
after initiation of supra-physiological doses of GH in a
15-year-old male with cSLE, though the patient subse-
quently developed worsening of lupus nephritis, which
improved following cessation of the GH treatment [29].
There are several limitations to our study. First, since
the height data in our cohort relies on participant self-
report, inaccuracies may occur. However, self- and
family member- reporting of heights are widely used in
the literature, and have been proven accurate in the
adult population [30, 31]. Second, since the LOS col-
lected data from individuals with cSLE in adulthood, we
do not have detailed data on exposures or outcomes that
occurred during childhood, such as cumulative steroid
exposure, disease activity measurements, nutritional
status or financial status. Since we lack information on
cumulative steroid exposure or steroid dosing during
childhood, the present study cannot assess whether the
effect of steroids on the final height is dose-dependent,
or whether there is a dose that minimizes the risk of
shorter-than-expected final height. Despite the absence
of disease activity measurements at the time of cSLE
diagnosis, it can be assumed that SLE is active at the
time of diagnosis. Therefore, if SLE was diagnosed at the
time of puberty, lupus activity and treatment may im-
pede the pubertal growth spurt, ultimately limiting adult
height. It is important to note that we do not have data
on the exact timing of puberty relative to SLE diagnosis,
e.g. age at menarche or Tanner stage at diagnosis. There-
fore, we used age as a proxy for the timing of the puber-
tal growth spurt. However, age may not accurately
reflect pubertal stage, especially among adolescents with
cSLE that may be at risk for delayed puberty. Similarly,
we do not have data to specify the timing of other events
that occurred in cSLE participants, such as the onset of
ESRD during childhood vs. adulthood. Third, the
number of male participants is our study was small,
which reflects the fact that SLE is much more common
in females. This reduced our power to detect statistically
Fig. 4 Adjusted Odds Ratios for Substantially Reduced Final Height among females with cSLE by age at diagnosis*. Females with cSLE diagnosed
between the ages of 11 and 13 years were at greatest risk for substantially reduced final height (final height > 2 standard deviations below mid-parental
target height), with an adjusted odds ratio of 11.2 as compared to participants with aSLE (95% CI + 3.4, + 36.3; p< 0.001). Analyses adjusted for
race/ethnicity, year of diagnosis, cyclophosphamide use and ESRD
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significant differences among male participants. Fi-
nally, it is important to note that our cSLE cohort is
on average younger than the aSLE cohort. Since
younger generations have become progressively taller
over the past century [32], as reflected by the fact
that our aSLE cohort was on average taller than mid-
parental target height, the true target height of our
cSLE cohort may actually be greater than their mid-
parental height. Therefore, the true difference in the
odds of clinically significant short stature between
our aSLE and cSLE cohorts may be greater than
reported here.
This study is the first to assess final adult height in
individuals with childhood-onset SLE, which is a more
accurate indicator of permanent damage than growth
failure. Our study also included data on mid-parental
height, which allowed us to account for the impact of
genetics in a multi-ethnic cohort.
Our study suggests that disease onset at the period of
maximum linear growth may predict shorter-than-
expected stature in adulthood. Per our results, clinicians
should closely monitor growth in patients with pubertal
onset of SLE and consider underlying pubertal develop-
ment in their determination of future risk for short stat-
ure. Treatment strategies that minimize steroid exposure
and promote tight disease control, including aggressive
use of second-line immunosuppressive agents, should be
applied when possible, as minimizing systemic inflam-
mation and steroid exposure may help to prevent short
stature in cSLE. Individuals with severe short stature
may benefit from GH therapy; however, further data is
needed in order to determine risk versus benefit and to
identify the sub-groups for whom this treatment is most
appropriate. The development of predictive models for
future short stature would be informed by prospective
studies that assess all potential risk factors for reduced
final height, including detailed assessments of disease
features, medication exposure and pubertal stage.
Conclusion
In conclusion, our study showed that childhood-onset
SLE is associated with shorter-than-expected final adult
height. Onset of SLE in the pubertal period, a time of
rapid linear growth, may have a particularly significant
impact on final adult height.
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